Sodium-glucose Cotransporter 2 Inhibitor-Associated Diabetic Ketoacidosis in Patients With Type 1 Diabetes: Metabolic Imbalance as an Underlying Mechanism
作者： Wataru Ogawa , Yushi Hirota
DOI: 10.1111/JDI.13026
关键词:
摘要: For type 1 diabetes patients with inadequate glycemic control, one treatment option is to increase the insulin dose (scenario 1), which should not give rise a "metabolic imbalance." A second additional sodium-glucose cotransporter 2 inhibitor, might lead imbalance" 2). reduction in addition administration of inhibitor further 3).
sci-hub.se 参考文章(16)
Wataru Ogawa, Kazuhiko Sakaguchi, Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors Journal of Diabetes Investigation. ,vol. 7, pp. 135- 138 ,(2016) , 10.1111/JDI.12401
Hadi Harati, Vandhna Sharma, Abbas Motazedi, Sodium‐glucose cotransporter 2 inhibitor‐associated diabetic ketoacidosis: Report of two cases with hyperglycemic ketoacidosis in type 1 diabetes Journal of Diabetes. ,vol. 8, pp. 165- 165 ,(2016) , 10.1111/1753-0407.12330
Jamie C. Diner, Irl B. Hirsch, Anne L. Peters, Elizabeth O. Buschur, John B. Buse, Pejman Cohan, Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition Diabetes Care. ,vol. 38, pp. 1687- 1693 ,(2015) , 10.2337/DC15-0843
Nicholas B. Argento, Katherine Nakamura, GLYCEMIC EFFECTS OF SGLT-2 INHIBITOR CANAGLIFLOZIN IN TYPE 1 DIABETES PATIENTS USING THE DEXCOM G4 PLATINUM CGM. Endocrine Practice. ,vol. 22, pp. 315- 322 ,(2016) , 10.4158/EP151016.OR
Vistasp Daruwalla, Hassan Tahir, Adil Wani, Jahnavi Sagi, Nour Daboul, EUGLYCEMIC DIABETIC KETOACIDOSIS AND SEVERE ACUTE KIDNEY INJURY SECONDARY TO OFF LABEL USE OF SODIUM GLUCOSE COTRANSPORTER-2 INHIBITOR IN A TYPE-1 DIABETIC PATIENT Journal of Ayub Medical College Abbottabad. ,vol. 27, pp. 923- 924 ,(2015)
Anne L. Peters, Robert R. Henry, Payal Thakkar, Cindy Tong, Maria Alba, Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes. Diabetes Care. ,vol. 39, pp. 532- 538 ,(2016) , 10.2337/DC15-1995
Nimrah Bader, Lubna Mirza, Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin. Pakistan Journal of Medical Sciences. ,vol. 32, pp. 786- 788 ,(2016) , 10.12669/PJMS.323.9201
Nitesh D. Kuhadiya, Husam Ghanim, Aditya Mehta, Manisha Garg, Salman Khan, Jeanne Hejna, Barrett Torre, Antoine Makdissi, Ajay Chaudhuri, Manav Batra, Paresh Dandona, Dapagliflozin as Additional Treatment to Liraglutide and Insulin in Patients With Type 1 Diabetes The Journal of Clinical Endocrinology and Metabolism. ,vol. 101, pp. 3506- 3515 ,(2016) , 10.1210/JC.2016-1451
Robert R. Henry, Paresh Dandona, Jeremy Pettus, Sunder Mudaliar, John Xu, Lars Hansen, Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting β-hydroxybutyrate levels in a phase IIa pilot study. Diabetes, Obesity and Metabolism. ,vol. 19, pp. 814- 821 ,(2017) , 10.1111/DOM.12882
Atsunori Kashiwagi, Hiroshi Maegawa, Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus Journal of Diabetes Investigation. ,vol. 8, pp. 416- 427 ,(2017) , 10.1111/JDI.12644